Months af­ter team­ing up on RTK in­hibitor Lenvi­ma, Ei­sai/Mer­ck win new FDA OK in liv­er can­cer

Ei­sai’s star can­cer drug Lenvi­ma — the sub­ject of a re­cent $300 mil­lion pact with Mer­ck — just got the green light from reg­u­la­tors to treat a new in­di­ca­tion in liv­er can­cer.

The drug, whose gener­ic name is lenva­tinib, was al­ready ap­proved by the FDA in 2015 to treat thy­roid can­cer, and in 2016 it won ap­proval for re­nal cell car­ci­no­ma. But the med has been lined up to take a shot at sev­er­al new in­di­ca­tions, in­clud­ing this lat­est OK in he­pa­to­cel­lu­lar car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER